As GLP-1 receptor agonists become among the most prescribed medications in history, a critical question is emerging that the obesity medicine field has been slow to confront: what happens to the psychological relationship with food when appetite suppression is pharmacologically imposed rather than behaviorally cultivated? A perspective published in the New England Journal of Medicine raises formal concern that these blockbuster drugs may be connected to eating disorder pathology — a finding with significant implications for the millions now on semaglutide, tirzepatide, and related agents.
The NEJM piece, appearing in the August 2026 issue, examines clinical and emerging epidemiological signals suggesting that GLP-1 receptor agonist use may be associated with the development or exacerbation of disordered eating behaviors. While the specific mechanisms and case data referenced in the full article require direct reading, the framing centers on how profound appetite suppression and altered food reward signaling — core pharmacological effects of this drug class — could interact with pre-existing vulnerability to restrictive or dysregulated eating patterns. The journal's decision to publish this as a named concern piece signals that the evidence has crossed a threshold of clinical seriousness.
This concern sits within a broader context that has been quietly building in eating disorder research communities. GLP-1 receptors are expressed in brain regions governing reward, satiety, and emotional regulation — meaning these drugs do not act on appetite in isolation. Prior observational data have flagged that rapid, drug-induced weight loss may trigger body image distortions and restrictive behaviors in susceptible individuals. Critically, standard prescribing protocols for GLP-1 agonists do not typically include screening for eating disorder history — a gap that clinicians and researchers have flagged but that regulatory guidance has not yet formally addressed. This publication may accelerate that conversation. The limitation here is that a perspective piece, even in NEJM, is not primary data; causal establishment requires prospective cohort studies with validated eating disorder instruments.